Ocular Therapeutix, Inc. (OCUL) SEC Filings & Earnings Calls

Loss of a senior executive could impact strategic initiatives and investor confidence

“Chief Strategy Officer departing for CEO role at another company”

Clinical trial failure risk for other programs

“The successful development and commercialization of our products or product candidates is highly uncertain.” · word for word

Dependence on DEXTENZA for current revenue

“All of our product revenue, net, was attributable to sales of DEXTENZA.” · word for word

GTN provision pressure on DEXTENZA margin

“We expect that GTN Provisions relative to gross DEXTENZA product sales will remain at this increased level or may increase further, for the remainder of 2026 and beyond.” · word for word

Litigation risk

“defend ourselves against legal proceedings, including the litigation brought against us by EyePoint, Inc.” · word for word

Clinical and regulatory risk remains high; NDA submission and FDA review outcomes are uncertain.

“AXPAXLI NDA submission planned for Q4 2026; pre-NDA meeting in Q3 2026; 505(b)(2) pathway may accelerate review”

Regulatory approval risk for AXPAXLI NDA; FDA discussions ongoing.

“Subject to ongoing formal discussions with the U.S. FDA.” · word for word

Clinical trial risk for SOL-R and HELIOS-3; no revenue yet.

“SOL-R Phase 3 non-inferiority trial in wet AMD on track for topline readout in 1Q 2027.” · word for word

Dependence on AXPAXLI regulatory approval

“We plan to submit an NDA with the FDA for marketing approval of AXPAXLI for the treatment of wet AMD based on the Week 52 data from the SOL-1 trial” · word for word

Increasing GTN provisions pressuring DEXTENZA margins

“Our total GTN Provisions for the three months ended March 31, 2026 and 2025 were 54.1% and 49.4%, respectively, of gross DEXTENZA product sales.” · word for word

Significant operating losses and cash burn

“Net cash used in operating activities was $66.0 million for the three months ended March 31, 2026” · word for word

Clinical trial failure risk

“The company is a pre-commercial biopharmaceutical company with significant dependence on the success of its clinical trials for AXPAXLI.”

Financing risk

“The company raised $475 million in gross proceeds to support its clinical programs, indicating ongoing need for capital.”

Key person risk

“The CEO's compensation package is heavily tied to stock price performance, and the company's success is closely linked to his leadership.”

Regulatory risk

“The company obtained a special protocol assessment agreement from the FDA, but regulatory approval is not guaranteed.”

Competition risk

“The company operates in a highly competitive biopharmaceutical market for retina treatments.”

Clinical trial failure risk

“Clinical trials of our product candidates, including AXPAXLI, may not be successful. If we experience delays or difficulties in enrollment, serious adverse events or side effects are identified, or any other unforeseen events occur in connection with clinical trials of any of our product candidates... we may incur additional costs or experience delays in com” · word for word

Regulatory approval risk

“We may experience unforeseen events that could delay or prevent our ability to receive marketing approval or commercialize our product candidates.” · word for word

Funding risk

“If we are unable to raise additional funds through equity or debt financings or other arrangements when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts” · word for word

Manufacturing single-source risk

“We have a single-site manufacturing facility for DEXTENZA, and we have a separate single-site manufacturing facility for product candidates that we use in our clinical trials and other research and development activities, including AXPAXLI.” · word for word

Clinical trial failure risk: SOL-1 data readout is binary and could significantly impact stock if negative.

“SOL-1 Phase 3 superiority trial results remain masked to date... Ocular plans to submit NDA for AXPAXLI in wet AMD based on SOL-1 52 Week data, pending positive results” · word for word

DEXTENZA revenue decline due to reimbursement challenges, though unit volume is growing.

“the reduction in net revenue was due to a significantly more challenging reimbursement environment for DEXTENZA in 2025” · word for word

Key executive temporary absence may cause operational disruption

“CFO/COO on medical leave; interim CFO appointed”

Clinical trial outcome risk; data readout in Q1 2026.

“SOL-1 Phase 3 trial for wet AMD; data expected Q1 2026.”

Regulatory risk remains; NDA submission contingent on positive year 1 data.

“Assuming the data are positive... Company expects to report top-line data from year 1 of the SOL-1 clinical trial during the first quarter of 2026.”

Clinical trial risk: SOL-1 and SOL-R data readouts may fail to meet endpoints.

“SOL-1 (Phase 3, wet AMD) superiority trial on track for Q1 2026 topline data” · word for word

Dilution risk from equity offering.

“net proceeds of ~$445 million from October 2025 equity offering” · word for word

DEXTENZA net revenue decline due to Medicare policy

“We believe that the year-over-year decrease in net product revenue is primarily attributable to the Medicare reimbursement cap, the impact of rebates and discounts, and the impact of the inclusion of DEXTENZA into the cost performance category of the Centers for Medicare & Medicaid Services’ Merit-based Incentive Payment System, or MIPS, for 2025.” · word for word

Clinical trial failure risk for AXPAXLI

“The successful development and commercialization of our products or product candidates is highly uncertain. This is due to the numerous risks and uncertainties associated with product development and commercialization.” · word for word

Significant operating losses and accumulated deficit

“We have a history of incurring significant operating losses. Our net losses were $201.3 million for the nine months ended September 30, 2025, and $193.5 million, $80.7 million, and $71.0 million for the years ended December 31, 2024, 2023 and 2022, respectively. As of September 30, 2025, we had an accumulated deficit of $1,092.4 million.” · word for word

Dependence on future capital raises

“Until such time, if ever, as we can generate product revenues sufficient to achieve profitability, we expect to finance our cash needs through equity offerings, debt financings, collaborations, strategic alliances, licensing arrangements, royalty agreements, and marketing and distribution arrangements.” · word for word